Sanofi: 5-Star Dividend Stocks Poised to Outperform

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, French pharmaceutical giant Sanofi (NYSE: SNY  ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Sanofi and see what CAPS investors are saying about the stock right now.

Sanofi facts

Headquarters (founded)

Paris (1970)

Market Cap

$114.4 billion



Trailing-12-Month Revenue

$46.9 billion


CEO Christopher Viehbacher (since 2008)
CFO Jermoe Contamine (since 2009)

Return on Equity (average, past 3 years)



$6 billion / $21 billion

Dividend Yield



GlaxoSmithKline (NYSE: GSK  )
Merck (NYSE: MRK  )
Pfizer (NYSE: PFE  )

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 981 members who have rated Sanofi believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, flynthewest, succinctly summed up the Sanofi bull case for our community:

Attach "Europe based" to nearly any company in this fall of 2012, and expect a measurable price discount. Add to that [Sanofi's] history of drug development and management coupled with the change growing population of drug consumers (read, more baby boomers aging), and you have a winner.

If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Sanofi may not be your top choice.

If that's the case, we've compiled a special free report for investors called "Secure Your Future With 9 Rock-Solid Dividend Stocks," which uncovers several other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2121443, ~/Articles/ArticleHandler.aspx, 10/28/2016 4:15:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,151.57 -18.11 -0.10%
S&P 500 2,126.43 -6.61 -0.31%
NASD 5,188.73 -27.24 -0.52%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 3:59 PM
SNY $38.85 Up +1.60 +4.30%
Sanofi CAPS Rating: *****
GSK $40.16 Down -0.26 -0.64%
GlaxoSmithKline CAPS Rating: ***
MRK $58.73 Down -2.56 -4.18%
Merck and Co. CAPS Rating: ****
PFE $31.93 Down -0.55 -1.69%
Pfizer CAPS Rating: ****